Asset Details
Do you wish to reserve the book?
Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy
Do you wish to request the book?
Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy
2025
Overview
Despite therapeutic advancements, malignant melanoma remains a leading cause of skin cancer-related mortality, with incidence continuing to rise globally. Traditional prognostic tools offer important clinical guidance but fail to capture the biological heterogeneity of melanoma or reliably predict responses to emerging therapies. In this review, we summarize recent advances in prognostic and predictive molecular biomarkers reported over the past five years. We discuss immunohistochemical and tissue-based markers, circulating biomarkers, microRNAs, and gene expression profiles that enhance risk stratification and inform surveillance strategies. We also review immune-related markers that may predict response to immune-checkpoint inhibitor therapy. Lastly, we highlight investigational biomarkers—including gene signatures, epigenomic alterations, and microbiome influences—that are shaping the future landscape. Together, these advances reflect a shift toward precision oncology in melanoma, with the integration of biomarker-driven strategies offering the potential to personalize treatment and improve patient outcomes.
Publisher
MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI)
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.